527 related articles for article (PubMed ID: 33841132)
1. Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy.
Hofschröer V; Najder K; Rugi M; Bouazzi R; Cozzolino M; Arcangeli A; Panyi G; Schwab A
Front Pharmacol; 2020; 11():586599. PubMed ID: 33841132
[TBL] [Abstract][Full Text] [Related]
2. Ion channels in control of pancreatic stellate cell migration.
Storck H; Hild B; Schimmelpfennig S; Sargin S; Nielsen N; Zaccagnino A; Budde T; Novak I; Kalthoff H; Schwab A
Oncotarget; 2017 Jan; 8(1):769-784. PubMed ID: 27903970
[TBL] [Abstract][Full Text] [Related]
3. Ion Channel Signature in Healthy Pancreas and Pancreatic Ductal Adenocarcinoma.
Schnipper J; Dhennin-Duthille I; Ahidouch A; Ouadid-Ahidouch H
Front Pharmacol; 2020; 11():568993. PubMed ID: 33178018
[TBL] [Abstract][Full Text] [Related]
4. Role of TRPC1 channels in pressure-mediated activation of murine pancreatic stellate cells.
Fels B; Nielsen N; Schwab A
Eur Biophys J; 2016 Oct; 45(7):657-670. PubMed ID: 27670661
[TBL] [Abstract][Full Text] [Related]
5. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives.
Wu Y; Zhang C; Jiang K; Werner J; Bazhin AV; D'Haese JG
Front Oncol; 2020; 10():621937. PubMed ID: 33520728
[TBL] [Abstract][Full Text] [Related]
6. Nanoparticle-based therapeutic strategies targeting major clinical challenges in pancreatic cancer treatment.
Tarannum M; Vivero-Escoto JL
Adv Drug Deliv Rev; 2022 Aug; 187():114357. PubMed ID: 35605679
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting tumor necrosis factor-alpha diminishes desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal adenocarcinoma.
Zhao X; Fan W; Xu Z; Chen H; He Y; Yang G; Yang G; Hu H; Tang S; Wang P; Zhang Z; Xu P; Yu M
Oncotarget; 2016 Dec; 7(49):81110-81122. PubMed ID: 27835602
[TBL] [Abstract][Full Text] [Related]
8. Reversal of pancreatic desmoplasia by a tumour stroma-targeted nitric oxide nanogel overcomes TRAIL resistance in pancreatic tumours.
Huang HC; Sung YC; Li CP; Wan D; Chao PH; Tseng YT; Liao BW; Cheng HT; Hsu FF; Huang CC; Chen YT; Liao YH; Hsieh HT; Shih YC; Liu IJ; Wu HC; Lu TT; Wang J; Chen Y
Gut; 2022 Sep; 71(9):1843-1855. PubMed ID: 34921062
[TBL] [Abstract][Full Text] [Related]
9. Disrupting the balance between tumor epithelia and stroma is a possible therapeutic approach for pancreatic cancer.
Wang Z; Li J; Chen X; Duan W; Ma Q; Li X
Med Sci Monit; 2014 Oct; 20():2002-6. PubMed ID: 25327552
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
Chandana S; Babiker HM; Mahadevan D
Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
[TBL] [Abstract][Full Text] [Related]
11. The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.
Fu Y; Liu S; Zeng S; Shen H
Mol Cancer; 2018 Feb; 17(1):62. PubMed ID: 29458370
[TBL] [Abstract][Full Text] [Related]
12. Desmoplasia in pancreatic ductal adenocarcinoma: insight into pathological function and therapeutic potential.
Cannon A; Thompson C; Hall BR; Jain M; Kumar S; Batra SK
Genes Cancer; 2018 Mar; 9(3-4):78-86. PubMed ID: 30108679
[TBL] [Abstract][Full Text] [Related]
13. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts.
Liu H; Shi Y; Qian F
Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881
[TBL] [Abstract][Full Text] [Related]
14. Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages.
Incio J; Suboj P; Chin SM; Vardam-Kaur T; Liu H; Hato T; Babykutty S; Chen I; Deshpande V; Jain RK; Fukumura D
PLoS One; 2015; 10(12):e0141392. PubMed ID: 26641266
[TBL] [Abstract][Full Text] [Related]
15. Desmoplasia of pancreatic ductal adenocarcinoma.
Pandol S; Edderkaoui M; Gukovsky I; Lugea A; Gukovskaya A
Clin Gastroenterol Hepatol; 2009 Nov; 7(11 Suppl):S44-7. PubMed ID: 19896098
[TBL] [Abstract][Full Text] [Related]
16. Modeling the mechanical stiffness of pancreatic ductal adenocarcinoma.
Kpeglo D; Hughes MDG; Dougan L; Haddrick M; Knowles MA; Evans SD; Peyman SA
Matrix Biol Plus; 2022 Jun; 14():100109. PubMed ID: 35399702
[TBL] [Abstract][Full Text] [Related]
17. Identification of distinct slow mode of reversible adaptation of pancreatic ductal adenocarcinoma to the prolonged acidic pH microenvironment.
Wu TC; Liao CY; Lu WC; Chang CR; Tsai FY; Jiang SS; Chen TH; Lin KM; Chen LT; Chang WW
J Exp Clin Cancer Res; 2022 Apr; 41(1):137. PubMed ID: 35410237
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic stellate cells and pancreas cancer: current perspectives and future strategies.
Haqq J; Howells LM; Garcea G; Metcalfe MS; Steward WP; Dennison AR
Eur J Cancer; 2014 Oct; 50(15):2570-82. PubMed ID: 25091797
[TBL] [Abstract][Full Text] [Related]
19. Integrated expression profiling of potassium channels identifys KCNN4 as a prognostic biomarker of pancreatic cancer.
Jiang S; Zhu L; Yang J; Hu L; Gu J; Xing X; Sun Y; Zhang Z
Biochem Biophys Res Commun; 2017 Dec; 494(1-2):113-119. PubMed ID: 29050937
[TBL] [Abstract][Full Text] [Related]
20. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).
Hosen SMZ; Uddin MN; Xu Z; Buckley BJ; Perera C; Pang TCY; Mekapogu AR; Moni MA; Notta F; Gallinger S; Pirola R; Wilson J; Ranson M; Goldstein D; Apte M
Front Immunol; 2022; 13():1060957. PubMed ID: 36591282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
